Dr Toni Choueiri discusses a new Phase 2 clinical trial on volitinib in patients with papillary renal cell carcinoma (pRCC)
At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new AstraZeneca-sponsored Phase 2 clinical trial o...
Author: EMJ
Added: 11/26/2014
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: AstraZeneca | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Harvard | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology